Equities Analysts Set Expectations for DNLI FY2025 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities researchers at Leerink Partnrs raised their FY2025 EPS estimates for Denali Therapeutics in a research note issued to investors on Sunday, November 9th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($2.95) per share for the year, up from their previous estimate of ($3.00). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Denali Therapeutics’ Q4 2025 earnings at ($0.71) EPS, FY2026 earnings at ($2.55) EPS and FY2027 earnings at ($2.65) EPS.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.02. The business’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.63) EPS.

Several other equities research analysts have also commented on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Denali Therapeutics in a research report on Monday, September 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Wednesday, October 8th. JPMorgan Chase & Co. increased their price target on shares of Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. TD Cowen upgraded shares of Denali Therapeutics to a “strong-buy” rating in a research report on Monday, July 28th. Finally, Morgan Stanley cut their price objective on shares of Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Monday, August 18th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Denali Therapeutics presently has an average rating of “Buy” and a consensus target price of $32.64.

Denali Therapeutics Stock Up 12.7%

Denali Therapeutics stock opened at $17.58 on Wednesday. The business’s 50-day moving average price is $15.13 and its 200 day moving average price is $14.70. The company has a quick ratio of 9.79, a current ratio of 9.79 and a debt-to-equity ratio of 0.01. The firm has a market cap of $2.58 billion, a price-to-earnings ratio of -6.04 and a beta of 1.39. Denali Therapeutics has a 52 week low of $10.57 and a 52 week high of $31.47.

Institutional Trading of Denali Therapeutics

Several institutional investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Denali Therapeutics by 88.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,766,916 shares of the company’s stock valued at $91,996,000 after buying an additional 3,184,042 shares in the last quarter. SCS Capital Management LLC purchased a new stake in Denali Therapeutics during the 1st quarter worth approximately $2,692,000. TT International Asset Management LTD acquired a new position in shares of Denali Therapeutics during the second quarter valued at approximately $909,000. Strs Ohio purchased a new position in shares of Denali Therapeutics in the first quarter valued at approximately $324,000. Finally, Millennium Management LLC boosted its stake in shares of Denali Therapeutics by 269.4% in the first quarter. Millennium Management LLC now owns 1,493,068 shares of the company’s stock worth $20,298,000 after acquiring an additional 1,088,844 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.